Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinomaResearch in context

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinomaResearch in context

Summary: Background: Simlukafusp alfa (FAP-IL2v) is an immune cytokine engineered to selectively promote immune responses in the tumour microenvironment. We evaluated the antitumour activity and safety of FAP-IL2v plus atezolizumab in recurrent and/or metastatic cervical squamous cell carcinoma (SC...

Full description

Saved in:
Bibliographic Details
Main Authors: Loic Verlingue, Antoine Italiano, Hans Prenen, Eva Maria Guerra Alia, Diego Tosi, Ruth Perets, Iwona Lugowska, Vladimir Moiseyenko, Mahmut Gumus, Cagatay Arslan, Colin R. Lindsay, Sanjeev Deva, Álvaro Taus, Ana Oaknin, Sylvie Rottey, Irfan Cicin, Sema Sezgin Goksu, Alexey Smolin, Susana Roselló-Keränen, Christin Habigt, Daniel Marbach, Christophe Boetsch, David Dejardin, Nassim Sleiman, Stefan Evers, Muriel Richard, Caroline Ardeshir, Jehad Charo, Anton Kraxner, Volker Teichgräber, Nino Keshelava, Rafal Dziadziuszko
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:EBioMedicine
Subjects:
Cervical cancer
Squamous cell carcinoma
Immunotherapy
IL-2
PD-L1
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396424004109
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2352396424004109

Similar Items